JAZZ (Jazz Pharma) Bathi resik saben saham (EPS TTM)

Jazz Pharmaceuticals maintains a positive outlook driven by its stable authority in sleep therapy, although the annual EPS TTM growth rate on the GURU.Markets chart exhibits volatility. This is driven by the threat of patent expirations and generic pressure, as well as fierce competition in neurobiology necessitating costly deals. The current value of 160.90 indicates the status of earnings relative to the company's multi-year cycles.
JAZZ (Jazz Pharmaceuticals PLC): rincian analitis lan laporan miturut indikator

For Jazz Pharmaceuticals (JAZZ), which is investing in the environmental modernization of its plants, the relative YoY EPS growth over the last 12 months serves as an indicator of cost management efficiency amid rising profits. This metric measures the percentage change in net income per share on a rolling annual basis, allowing for an assessment of the company's real income and capital resilience under tight monetary policy.